David Francis McDermott MD

Associate Professor, Medicine, Harvard Medical School; Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center; Director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center

Join to view full profile

330 Brookline AveBoston, MA 02215
Phone+1 617-667-2100

Dr. McDermott is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McDermott's full profile Already have an account?

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
Tufts Medical CenterResidency, Internal Medicine, 1992 - 1995
Weill Cornell MedicineClass of 1992

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1998 - 2026
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification Quality Data Center, Massachusetts eHealth Collaborative (MAeHC), 2012, 2014-2017
CMS Meaningful Use Stage 1 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification Online Medical Record, Beth Israel Deaconess Medical Center, 2012, 2014-2017

Clinical Trials

Paclitaxel and Carboplatin in Treating Patients With Locally Advanced or Metastatic Renal Cell Cancer Start of enrollment: 2006 Jun 01
COMPLETED
PHASE2
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer Start of enrollment: 2007 Sep 14
COMPLETED
PHASE2
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
COMPLETED
PHASE2

Publications & Presentations

PubMed

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Nourhan El Ahmar, Morgan A Paul, Berkay Simsek, Sayed Matar, Opeyemi A Jegede
Clinical Cancer Research. 2026-08-14
The clinical landscape of HIF2α inhibitors in oncology.
Eddy Saad, Marc Machaalani, David F McDermott, Toni K Choueiri
Nature Reviews. Clinical Oncology. 2026-07-01
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Rana R McKay, Michael Serzan, Wanling Xie, Bradley A McGregor, David Braun
Journal for Immunotherapy of Cancer. 2026-07-01

Journal Articles

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell Carcinoma
Praful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...
Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Carcinoma
Michael B Atkins, Thomas Hutson, Mario Sznol, Toni K Choueiri, Sumanta K Pal, Richard W Joseph, John Hainsworth, W Kimryn Rathmell, David F McDermott, Robert J Motzer,..., Nature

Lectures

CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcino...
2019 ASCO Annual Meeting - 6/1/2019
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020

Press Mentions

A ‘Paradigm Shift’: Moderna Cancer Vaccine Results Could Herald New World of TreatmentAugust 19th, 2026
Advancing RCC Treatment: Biomarkers, Combination Therapies, and Emerging InnovationsJanuary 8th, 2025
Researchers Discuss Future of Cancer Therapies at 15th Annual Cancer SymposiumNovember 11th, 2022

Grant Support

Developing a Translation Pipeline for VHL Mutant MalignanciesBETH ISRAEL DEACONESS MEDICAL CENTER2019–2028
Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell CarcinomaBETH ISRAEL DEACONESS MEDICAL CENTER2021–2026
DF/HCC Kidney Cancer SPORE (supplement)BETH ISRAEL DEACONESS MEDICAL CENTER2003–2026
DF/HCC Kidney Cancer SPORE (supplement)BETH ISRAEL DEACONESS MEDICAL CENTER2003–2026
DF/HCC Kidney Cancer SPORE (supplement)BETH ISRAEL DEACONESS MEDICAL CENTER2003–2026